

Fax completed prior authorization request form to 855-247-3677 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts.

All requested data must be provided. Incomplete forms or forms without the chart notes will be returned

Pharmacy Coverage Guidelines are available at www.mercycareaz.org/providers/rbha- forproviders/pharmacy

Xolair Pharmacy Prior Authorization Request Form Do not copy for future use. Forms are updated frequently. and medical testing relevant to request showing medical justification are

Member Name (first & last):	Date of Birth:		Gender:				Height:			
,						male				
Member ID:	City:		State:				Weight:			
Prescribing Provider Information										
Provider Name (first & last):	Specialty:			NPI#			DEA#			
Office Address:	City:	State:			Zip Code:					
Office Contact:	Of	ffice Phone	Office Fax:			Fax:				
Dispensing Pharmacy Information										
Pharmacy Name:	Pharmacy Phone:			Pharmacy Fa			ax:			
Requested Medication Information										
What medication(s) has member tried and fa Please specify:	iled for this dia	ignosis?								
Medication request is NOT for an FDA- app supported diagnosis (circle one): Yes	proved, or com	mpendia- Diagnosis:			ICD-10 Code:					
Are there any contraindications to formulary							□ Ye	ne .		No
If yes, please specify:	medications:						<u></u> п	53	_	NO
Directions for Use:	St	Strength:			Dosage Form:					
	Qı	uantity:	Day Supply: Duration		on of Th	n of Therapy/Use:				
Turn-Around Time for Review										
□ Standard – (24 hours)		ent – waiting 24 hour								ealth,
			regain maximum function, you can asl			or an expedited decision.				
Clinical Information										
□ Moderate to Severe Asthma										
	□ Poor symptom control (ACQ score >1.5 or ACT score <20) □ 2 or more bursts of systemic steroids for at least 3 days each in previous 12 months									
Classification of asthma as uncontrolled OR controlled as defined by ONE of the following		☐ Asthma-related emergency TX (ER visit, hospital admit OR unscheduled DR's office visit for nebulizer OR other urgent TX)								
		Airflow limitation (after appropriate bronchodilator withhold FEV1 <80% predicted defined as less than lower limit of normal)								
		☐ Member is cu						asth	nma	
 □ Baseline (pre-omalizumab TX) serum to ≥ 30 IU/mL AND ≤ 1500 IU/mL 	☐ Member is currently dependent on oral steroids for TX of asthma			re	Positive skin test OR in vitro eactivity to a perennial eroallergen					
☐ Use of ONE MAX-dosed COMBO ICS-LABA [fluticasone propionate- salmeterol (AirDuo, Advair), budesonide-formoterol (Symbicort)]	[ciclesonion furoate (A	NE high-dose ICS de (Alvesco), mome smanex), beclometh ate (QVAR)]		Use of one ADD'L asthma controller (LAE olodaterol (Striverdi) OR indacaterol (Arcapta); leukotriene receptor antagonist montelukast (Singulair); theophylline]						
Is the member receiving Xolair with Nucala, I	Fasenra, Cinqa	air OR Dupixent?		1			Yes		l N	lo
□ Renewal Requests ONLY										

Effective: 10/01/2022 C23396-A

		☐ Reduction in frequency of exacerbations	☐ Decreased utilization of rescue medications							
Documentation of positive clinical response as demonstrated by ONE of the following:		Reduction in severity OR frequency of asthma-related symptoms (wheezing, SOB, coughing)	□ Increase in % predicted FEV1 from pre-TX baseline							
☐ Xolair is used in COMBO with an containing controller medication	ICS-	Is the member receiving Xolair with Nucala, Fasenra, Cinqair OR Dupixent?								
□ Chronic Idiopathic Urticaria										
☐ Member remains symptomatic despite at least a 2-week trial of OR HX of C/I or intolerance with TWO H1-antihistamines [Allegra (fexofenadine), Benadryl (diphenhydramine), Claritin (loratadine)]										
Member remains symptomatic despite at least a 2-week trial of OR HX of C/I or intolerance to the following taken in combination: 2 nd generation H1-antihistamine [Allegra (fexofenadine), Claritin (loratadine), Zyrtec (cetirizine)]										
Member has ONE of the following:		A different 2 nd generation H1-antihistamine [Allegra (fexofenadine), Claritin (loratadine), Zyrtec (cetirizine)]								
	☐ H2-ar	antihistamine [Pepcid (famotidine), Tagamet HB (cimetidine), Zantac (ranitidine)]								
		eneration H1-antihistamine [Benadryl (diphenhydramine), Chlor-Trimeton orpheniramine), Vistaril (hydroxyzine)]								
	☐ Leuko	triene modifier [Singulair (montelukast)]								
□ Renewal Requests ONLY										
Is there documentation of positive clir	nical respon	se to therapy (reduction in exacerbations, itch s	everity, hives)?							
Additional information the prescribing provider feels is important to this review. Please specify below or submit medical records.										
Signature affirms that information given on this form is true and accurate and reflects office notes.										
Prescribing Provider's Signature:			Date:							

Please note: Incomplete forms or forms without the chart notes will be returned

Office notes, labs, and medical testing relevant to the request that show medical justification are required.

Standard turnaround time is 24 hours. You can call 800-564-5465 to check the status of a request.

Effective: 10/01/2022 C23396-A